These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38392571)

  • 1. Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art.
    Faiella E; Santucci D; Vertulli D; Vergantino E; Vaccarino F; Perillo G; Beomonte Zobel B; Grasso RF
    J Pers Med; 2024 Jan; 14(2):. PubMed ID: 38392571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer.
    Scheltema MJ; Geboers B; Blazevski A; Doan P; Katelaris A; Agrawal S; Barreto D; Shnier R; Delprado W; Thompson JE; Stricker PD
    BJU Int; 2023 Jun; 131 Suppl 4():6-13. PubMed ID: 36495481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer.
    van Riel LAMJG; Geboers B; Kabaktepe E; Blazevski A; Reesink DJ; Stijns P; Stricker PD; Casanova J; Dominguez-Escrig JL; de Reijke TM; Scheltema MJ; Oddens JR
    BJU Int; 2022 Nov; 130(5):611-618. PubMed ID: 35474600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
    Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
    Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer.
    Geboers B; Scheltema MJ; Blazevski A; Katelaris A; Doan P; Ali I; Agrawal S; Barreto D; Matthews J; Haynes AM; Delprado W; Shnier R; Thompson JE; Stricker PD
    BJU Int; 2023 Jun; 131 Suppl 4():14-22. PubMed ID: 36594205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.
    Guenther E; Klein N; Zapf S; Weil S; Schlosser C; Rubinsky B; Stehling MK
    PLoS One; 2019; 14(4):e0215093. PubMed ID: 30986263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal irreversible electroporation as primary treatment for localized prostate cancer.
    van den Bos W; Scheltema MJ; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2018 May; 121(5):716-724. PubMed ID: 28796935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study.
    Yaxley WJ; Gianduzzo T; Kua B; Oxford R; Yaxley JW
    Investig Clin Urol; 2022 May; 63(3):285-293. PubMed ID: 35534217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
    Blazevski A; Scheltema MJ; Amin A; Thompson JE; Lawrentschuk N; Stricker PD
    BJU Int; 2020 Mar; 125(3):369-378. PubMed ID: 31725935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy.
    Scheltema MJ; Chang JI; Böhm M; van den Bos W; Blazevski A; Gielchinsky I; Kalsbeek AMF; van Leeuwen PJ; Nguyen TV; de Reijke TM; Siriwardana AR; Thompson JE; de la Rosette JJ; Stricker PD
    World J Urol; 2018 Sep; 36(9):1383-1389. PubMed ID: 29594551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SAFE Pilot Trial-SAlvage Focal Irreversible Electroporation-For Recurrent Localized Prostate Cancer: Rationale and Study Protocol.
    Marra G; Shah TT; D'Agate D; Marquis A; Calleris G; Lunelli L; Filippini C; Oderda M; Gatti M; Valerio M; Sanchez-Salas R; Bossi A; Gomez-Rivas J; Conte F; Deandreis D; Cussenot O; Ricardi U; Gontero P
    Front Surg; 2022; 9():900528. PubMed ID: 35747441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
    Blazevski A; Amin A; Scheltema MJ; Balakrishnan A; Haynes AM; Barreto D; Cusick T; Thompson J; Stricker PD
    World J Urol; 2021 Apr; 39(4):1107-1114. PubMed ID: 32488359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible Electroporation for the Ablation of Prostate Cancer.
    Karagiannis A; Varkarakis J
    Curr Urol Rep; 2019 Sep; 20(10):63. PubMed ID: 31478109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
    BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes.
    Blazevski A; Gondoputro W; Scheltema MJ; Amin A; Geboers B; Barreto D; Haynes AM; Shnier R; Delprado W; Agrawal S; Thompson JE; Stricker PD
    BMC Urol; 2022 Mar; 22(1):28. PubMed ID: 35236338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irreversible electroporation as a focal therapy for localized prostate cancer: A systematic review.
    Prabhakar P; Avudaiappan AP; Sandman M; Eldefrawy A; Caso J; Narayanan G; Manoharan M
    Indian J Urol; 2024; 40(1):6-16. PubMed ID: 38314081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Treatment Strategy in "Low-Risk Prostate Cancer Active Surveillance Candidates" Using Irreversible Electroporation: Prospective Evaluation of Feasibility, Morbidity, Functional and Oncological Outcomes.
    Popeneciu IV; Mohr MN; Strauß A; Leitsmann C; Trojan L; Reichert M
    World J Mens Health; 2024 Oct; 42(4):821-829. PubMed ID: 38311374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control.
    Ting F; Tran M; Böhm M; Siriwardana A; Van Leeuwen PJ; Haynes AM; Delprado W; Shnier R; Stricker PD
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):46-52. PubMed ID: 26458959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial.
    Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J
    JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.